Clifford Chance, Ropes and Skadden take roles on Pfizer's $17bn Hospira takeover
Pharmaceutical giant turns to Clifford Chances and Ropes & Gray for deal to boost its product portfolio
Clifford Chance, Ropes & Gray and Skadden Arps Slate Meagher & Flom have been called up as advisers for Pfizer’s $17bn (£11bn) acquisition of injectable drugmaker Hospira.
This premium content is reserved for
Legal Week Subscribers.
Subscribe today and get 10% off.
A PREMIUM SUBSCRIPTION PROVIDES:
- Trusted insight, news and analysis from the UK and across the globe
- Connections to senior business lawyers within the leading law firms and legal departments
- Optimized access on all of your devices: desktop, tablet and mobile
- Complete access to the site's full archive of more than 56,000 articles
Already have an account? Sign In Now